Skip to content
10-Q

Quarterly Report

Aurinia Pharmaceuticals Inc. AUPH

0001600620-26-000049

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 128.6M sh
Shares Diluted Q1 2026 · Mar 31, 2026 137.64M sh
Shares Diluted Q1 2026 · Mar 31, 2025 143.2M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $36.17M
Stock Repurchased Q1 2026 · Mar 31, 2025 $46.92M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $32.56M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $1.3M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $40.75M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $66.11M
Stockholders Equity Q1 2026 · Mar 31, 2026 $567.63M
Stockholders Equity Q1 2026 · Dec 31, 2025 $581.33M
Stockholders Equity Q1 2026 · Mar 31, 2025 $350.19M
Stockholders Equity Q1 2026 · Dec 31, 2024 $377.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $86.56M
Current Liabilities Q1 2026 · Dec 31, 2025 $93.72M
Total Liabilities Q1 2026 · Mar 31, 2026 $156.37M
Total Liabilities Q1 2026 · Dec 31, 2025 $170.26M
Current Assets Q1 2026 · Mar 31, 2026 $480.24M
Current Assets Q1 2026 · Dec 31, 2025 $491.97M
Total Assets Q1 2026 · Mar 31, 2026 $724M
Total Assets Q1 2026 · Dec 31, 2025 $751.59M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.25
Eps Diluted Q1 2026 · Mar 31, 2025 $0.16
Eps Basic Q1 2026 · Mar 31, 2026 $0.26
Eps Basic Q1 2026 · Mar 31, 2025 $0.17
Rd Expense Q1 2026 · Mar 31, 2026 $7.47M
Rd Expense Q1 2026 · Mar 31, 2025 $5.74M
Net Income Q1 2026 · Mar 31, 2026 $34.36M
Net Income Q1 2026 · Mar 31, 2025 $23.34M
Operating Income Q1 2026 · Mar 31, 2026 $41.42M
Operating Income Q1 2026 · Mar 31, 2025 $21.85M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $6.51M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $8.57M
Revenue Q1 2026 · Mar 31, 2026 $77.71M
Revenue Q1 2026 · Mar 31, 2025 $62.47M